Compare BIRK & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIRK | BLTE |
|---|---|---|
| Founded | 1774 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.0B |
| IPO Year | 2023 | 2021 |
| Metric | BIRK | BLTE |
|---|---|---|
| Price | $30.01 | $169.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $61.43 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 2.4M | 182.2K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $14.30 | $492.11 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.25 | $65.00 |
| 52 Week High | $50.73 | $200.00 |
| Indicator | BIRK | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 28.97 | 54.32 |
| Support Level | N/A | $167.80 |
| Resistance Level | $37.29 | $182.61 |
| Average True Range (ATR) | 1.18 | 8.34 |
| MACD | -0.24 | 0.96 |
| Stochastic Oscillator | 6.08 | 47.17 |
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.